Dinaciclib information

Dinaciclib
Clinical data
Other names	SCH-727965
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (S)-3-(((3-Ethyl-5-(2-(2-hydroxyethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl)amino)methyl)pyridine 1-oxide;
CAS Number	779353-01-4;
PubChem CID	46926350;
IUPHAR/BPS	7379;
ChemSpider	25027387;
UNII	4V8ECV0NBQ;
KEGG	D09604;
ChEMBL	ChEMBL2103840;
PDB ligand	1QK (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID90999131 ;
ECHA InfoCard	100.246.885
Chemical and physical data
Formula	C21H28N6O2
Molar mass	396.495 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCC[C@H]4CCO;
	InChI InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1; Key:PIMQWRZWLQKKBJ-SFHVURJKSA-N;

Dinaciclib (SCH-727965) is an experimental drug that inhibits cyclin-dependent kinases (CDKs).^[1] It is being evaluated in clinical trials for various cancer indications.^[2]

Dinaciclib is being developed by Merck & Co. It was granted orphan drug status by the FDA in 2011.^[3]

^ Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, et al. (August 2010). "Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor". Molecular Cancer Therapeutics. 9 (8): 2344–2353. doi:10.1158/1535-7163.MCT-10-0324. PMID 20663931.
^ Bose P, Simmons GL, Grant S (June 2013). "Cyclin-dependent kinase inhibitor therapy for hematologic malignancies". Expert Opinion on Investigational Drugs. 22 (6): 723–738. doi:10.1517/13543784.2013.789859. PMC 4039040. PMID 23647051.
^ "Dinaciclib". AdisInsight. Springer Nature Switzerland AG. Retrieved 31 January 2017.

[1] Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, et al. (August 2010). "Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor". Molecular Cancer Therapeutics. 9 (8): 2344–2353. doi:10.1158/1535-7163.MCT-10-0324. PMID 20663931.

[pmid23647051-2] Bose P, Simmons GL, Grant S (June 2013). "Cyclin-dependent kinase inhibitor therapy for hematologic malignancies". Expert Opinion on Investigational Drugs. 22 (6): 723–738. doi:10.1517/13543784.2013.789859. PMC 4039040. PMID 23647051.

[Adis-3] "Dinaciclib". AdisInsight. Springer Nature Switzerland AG. Retrieved 31 January 2017.

Dinaciclib information

and 4 Related for: Dinaciclib information

Dinaciclib

CDK inhibitor

Meenhard Herlyn

CSNK1D